• Corpus ID: 27198164

Inhibitor of beta-hydroxy-beta-methylglutaryl coenzyme A reductase decreases energy supply to the myocardium in rats.

@article{Pisarenko2001InhibitorOB,
  title={Inhibitor of beta-hydroxy-beta-methylglutaryl coenzyme A reductase decreases energy supply to the myocardium in rats.},
  author={Oleg Pisarenko and Irina Studneva and Vadim Z. Lankin and Galina G. Konovalova and Alla K. Tikhaze and Violetta I Kaminnaya and Yu. N. Belenkov},
  journal={Bulletin of experimental biology and medicine},
  year={2001},
  volume={132 4},
  pages={
          956-8
        }
}
Hypocholesterolemic preparations, inhibitors of the key enzyme of cholesterol biosynthesis beta-hydroxy-beta-methylglutaryl coenzyme A reductase (statins), block the synthesis of ubiquinone Q10, intermediate electron carrier in the mitochondrial respiratory chain. This should decrease energy supply to tissues. Daily peroral administration of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor simvastatin (24 mg/kg perorally) for 30 days had no effect on the contents of macroergic… 
View on PubMed
7 Citations
Highly Influential Citations
1
Background Citations
6

7 Citations

Citation Type

Citation Type

HMG CoA reductase inhibition by Simvastatin gets rat β -Myosin heavy chain disappeared: A statin paradox
TLDR
The results showed that simvastatin treatment leads to a reduced amount of rat ventricle ubiquinone and to β myosin heavy chain disappearance, indicating that statins which are prescribed to prevent cardiovascular disease, might induce cardiac metabolic and structural modifications whose functional implications on contractility are still to be established and carefully considered.
Simvastatin decreased coenzyme Q in the left ventricle and skeletal muscle but not in the brain and liver in L-NAME-induced hypertension.
TLDR
The administration of simvastatin under the condition of NO-deficiency reduced the level of CoQ in the heart and skeletal muscle what may participate in adverse effect of statins under certain clinical conditions.
Reduction of Infarct Size by Short-Term Pretreatment with Atorvastatin
TLDR
In conclusion, short-term (3 days) atorvastatin (10–75 mg/kg/d) significantly reduced myocardial infarct size and the protective effect was completely abolished by L-NAME, strongly suggesting that this protective effect is mediated via the nitric oxide synthase pathway.
The clinical use of HMG CoA‐reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications
The depletion of the essential nutrient CoQ10 by the increasingly popular cholesterol lowering drugs, HMG CoA reductase inhibitors (statins), has grown from a level of concern to one of alarm. With…
Effects of simvastatin on cardiohemodynamic responses to ischemia–reperfusion in isolated rat hearts
TLDR
Assessment of the cardioprotective effect of acute simvastatin treatment on isolated rat hearts found it could be applied just after myocardial ischemia and reperfusion, and exerted beneficial effects on cardiac function in isolated perfused rat hearts.
Cardiovascular effects of resveratrol and atorvastatin treatments in an H2O2-induced stress model
TLDR
Pretreatment with R+A for CVD appears to be superior to pretreatment with either agent alone, and this effect was mediated via the vascular endothelium.
Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?

References

Methods of Enzymatic Analysis